Despite the substantially greater mutation rate in normal tissues from POLE/POLD1 mutation carriers than from MMR gene mutation carriers, the estimated risk of colorectal cancer by age 70 is only moderately higher in POLE (90%) than in MLH1/MSH2 (41–48%) gene mutation carriers4,24. The gene discussed is POLE; the disease is colorectal cancer.